Sum­mit shares rock­et up, fu­eled by an $842M pact with Duchenne leader Sarep­ta

With its mar­ket cap swelled by the FDA’s ap­proval of the con­tro­ver­sial Duchenne mus­cu­lar dy­s­tro­phy drug eteplirsen, Sarep­ta is now wheel­ing and deal­ing its way …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER